Congress of the Spanish Society of Clinical Pharmacology. Santiago de Compostela, ESP, 1998/10/01.
As the financial resources available for looking after the health of an aging population are limited, generic drugs (drugs that are no longer covered by a patent and marketed at a lower price) have come to be used in western countries as a means for meeting growing demand while leaving resources in the health budget for new drugs.
In Spain, a law on product patents was introduced in 1992, which is much later than in other countrie and created difficulties in the definition and procedure for gaining approval for generic drugs.
Circular 3/97 from the Ministry of Health finally resolved these issues.
In this circular, generic pharmaceutical products (GPPs) are clearly defined and identified with a positive commitment towards guaranteeing the ability to interchange original drugs for other cheaper generic products and towards clarifying the Spanish vade mecum.
The position of the pharmaceutical industry on generic drugs varies widely and consequently, it is impossible to make a general statement on the view of the industry.
However, the commitment of Novartis, given the issues described above and in line with the company's global strategy, is to offer innovation and services to society, This is perfectly compatible with offering health professionals both innovative drugs and genetic drugs of a high quality at alower price, given that registering generics requires less investment in research and development. (...)
Mots-clés Pascal : Industrie pharmaceutique, Médicament générique, Recherche développement, Espagne, Europe, Article synthèse, Ministère, Economie santé, Stratégie entreprise, Information thérapeutique, Médecin, Pharmacien, Novartis
Mots-clés Pascal anglais : Pharmaceutical industry, Generic drug, Research and development, Spain, Europe, Review, Ministry, Health economy, Firm strategy, Therapeutic information, Physician, Chemist
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0091574
Code Inist : 002B30A08. Création : 31/05/1999.